These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 2992371)

  • 1. Preclinical assessment of topical treatments of herpes simplex virus infection: 5% (E)-5-(2-bromovinyl)-2'-deoxyuridine cream.
    Freeman DJ; Sacks SL; De Clercq E; Spruance SL
    Antiviral Res; 1985 Jun; 5(3):169-77. PubMed ID: 2992371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infection.
    Spruance SL; McKeough MB; Cardinal JR
    Antimicrob Agents Chemother; 1984 Jan; 25(1):10-5. PubMed ID: 6703671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of topically applied 5-ethyl-2'-deoxyuridine and acyclovir in the treatment of cutaneous herpes simplex virus infection in guinea pigs.
    Spruance SL; Freeman DJ; Sheth NV
    Antimicrob Agents Chemother; 1985 Jul; 28(1):103-6. PubMed ID: 4037770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of correlation between skin target site free drug concentration and the in vivo topical antiviral efficacy in hairless mice for (E)-5-(2-bromovinyl)-2'-deoxyuridine and acyclovir formulations.
    Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; De Clercq E; El-Shattawy HH
    J Pharm Sci; 1998 Aug; 87(8):917-21. PubMed ID: 9687333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Problems associated with the use of (E)-5-(2-bromovinyl)-2'-deoxyuridine for typing herpes simplex virus.
    Swierkosz EM; Arens MQ; Rivetna KA
    J Clin Microbiol; 1985 Mar; 21(3):459-61. PubMed ID: 2984249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
    de Clercq E
    Antimicrob Agents Chemother; 1984 Aug; 26(2):155-9. PubMed ID: 6486759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of topical treatment for herpes simplex virus infections: predictions from an index of drug characteristics in vitro.
    Freeman DJ; Spruance SL
    J Infect Dis; 1986 Jan; 153(1):64-70. PubMed ID: 3079810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel animal model for evaluating topical efficacy of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous herpes simplex virus type 1 (HSV-1) infections in hairless mice.
    Lee PH; Su MH; Kern ER; Higuchi WI
    Pharm Res; 1992 Aug; 9(8):979-89. PubMed ID: 1329068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different in vitro effects of dual combinations of anti-herpes simplex virus compounds.
    Schinazi RF; Nahmias AJ
    Am J Med; 1982 Jul; 73(1A):40-8. PubMed ID: 6285731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapeutic efficacy of E-5-(2-bromovinyl)-2'deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice.
    Park NH; Pavan-Langston D; Boisjoly HM; De Clercq E
    J Infect Dis; 1982 Jun; 145(6):909-13. PubMed ID: 6979592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection.
    Spruance SL; Freeman DJ; Sheth NV
    Antimicrob Agents Chemother; 1986 Jul; 30(1):196-8. PubMed ID: 2944480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral and topical treatment of experimental HSV-1 genital herpes with (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Sim IS
    J Antimicrob Chemother; 1984 Aug; 14 Suppl A():111-8. PubMed ID: 6541647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.
    de Clercq E; Zhang ZX; Sim IS
    Antimicrob Agents Chemother; 1982 Sep; 22(3):421-5. PubMed ID: 7137983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir.
    Reefschläger J; Wutzler P; Thiel KD; Herrmann G
    Antiviral Res; 1986 Mar; 6(2):83-93. PubMed ID: 3010858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of topical acyclovir in ointment to penetrate human skin.
    Freeman DJ; Sheth NV; Spruance SL
    Antimicrob Agents Chemother; 1986 May; 29(5):730-2. PubMed ID: 3729337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation of herpes simplex virus types 1 and 2 by sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Mayo DR
    J Clin Microbiol; 1982 Apr; 15(4):733-6. PubMed ID: 6279696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs.
    Helbig B; Sauerbrei A; Klöcking R; Wutzler P; Wicht N; Wiedemann U; Herrmann G
    J Med Virol; 1987 Nov; 23(3):303-9. PubMed ID: 2828526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice.
    Park NH; Pavan-Langston D; de Clercq E
    Antiviral Res; 1983 Mar; 3(1):7-15. PubMed ID: 6870230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged herpes simplex virus latency in vitro after treatment of infected cells with acyclovir and human leukocyte interferon.
    Scheck AC; Wigdahl B; De Clercq E; Rapp F
    Antimicrob Agents Chemother; 1986 Apr; 29(4):589-93. PubMed ID: 3010847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
    Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
    Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.